Axim expands IP with cannabinoid suppository patent
The US Patent and Trademark Office has granted Axim Biotechnologies patent 10,092,538, covering the firm’s cannabinoid suppository composition.
According to Axim, its formulation enables easy absorption through the mucosal membrane and is designed to treat patients with pain, nausea and vomiting, as well as patients with symptoms and conditions that prevent swallowing.
“Certain patients have gagging reflex and have a hard time swallowing, some have impaired swallowing reflexes,” CEO George Anastassov told us.
“Some are minors, or are physically/mentally impaired and run the risk of aspirating swallowed material. Some don’t like injections, etc.,” he continued.
Axim plans to use the patented formulation for its clinical programme targeting gastrointestinal conditions (GI), such as post-operative ileus and/or inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS).
The firm is contemplating continuous research studies for both its suppository product and CanChew Rx cannabidiol controlled-release chewing gum in the Netherlands, where earlier this month, the firm was awarded a good manufacturing practice (GMP) license to produce cannabis-derived candidates for the clinic.
